ROMAINVILLE, France--(BUSINESS WIRE)--Parc Biocitech -- Cellectis bioresearch, a subsidiary of the genome engineering company Cellectis SA (Paris:ALCLS), announced today that it has launched cGPS® Custom, a new line of kits for targeted gene integration in native cell lines. This is a breakthrough technology that will enable life science researchers to customize their own cell lines.
